Whitehawk Therapeutics (WHWK) EBITDA Margin (2018 - 2025)
Whitehawk Therapeutics (WHWK) posted quarterly EBITDA Margin of 212.99% for Q1 2025, up 15152.0% year-over-year from N/an in Q1 2024, and up 18.63% quarter-over-quarter from 261.76% in Q4 2024.
Powered by 
Analysis
Whitehawk Therapeutics (WHWK) EBITDA Margin (2018 - 2025) Analysis & Trends
Whitehawk Therapeutics (WHWK) has reported EBITDA Margin for 7 consecutive years, with 212.99% the latest figure, recorded in Q1 2025.
- In Q1 2025, EBITDA Margin rose 15152.0% year-over-year to 212.99%; the TTM figure through Dec 2025 stood at 1601.12% (down 134150.0% YoY), while the FY2025 annual figure was 1601.12%, down 134150.0% from the prior year.
- EBITDA Margin rose to 212.99% in Q1 2025 per WHWK's latest filing, from 261.76% in the prior quarter.
- Across five years, EBITDA Margin topped out at 113.89% in Q4 2021 and bottomed at 3405.83% in Q1 2021.
- Historically, EBITDA Margin has averaged 517.45% across 5 years, with a median of 296.0% in 2022.
- On a YoY basis, EBITDA Margin climbed as much as 280705 bps in 2022 and fell as far as 18211 bps in 2022.
- Whitehawk Therapeutics' EBITDA Margin stood at 113.89% in 2021, then tumbled by 160 bps to 296.0% in 2022, then grew by 5 bps to 280.02% in 2023, then increased by 7 bps to 261.76% in 2024, then grew by 19 bps to 212.99% in 2025.
- Business Quant data shows WHWK's EBITDA Margin at 212.99% in Q1 2025, 261.76% in Q4 2024, and 185.98% in Q3 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -562.07% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 19.06% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 17.93% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 19.75% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.36% |
| 10 | Whitehawk Therapeutics | 377.13 Mn | 377.13 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | -212.99% |
| Dec 31, 2024 | -261.76% |
| Sep 30, 2024 | -185.98% |
| Jun 30, 2024 | -252.21% |
| Mar 31, 2024 | -364.51% |
| Dec 31, 2023 | -280.02% |
| Sep 30, 2023 | -299.53% |
| Jun 30, 2023 | -315.14% |
| Mar 31, 2023 | -286.77% |
| Dec 31, 2022 | -296.00% |
| Sep 30, 2022 | -354.20% |
| Jun 30, 2022 | -534.19% |
| Mar 31, 2022 | -598.79% |
| Dec 31, 2021 | -113.89% |
| Mar 31, 2021 | -3,405.83% |
| Dec 31, 2020 | 60.03% |
| Sep 30, 2020 | -1,152.81% |
| Jun 30, 2020 | 61.71% |
| Dec 31, 2018 | -413,534.42% |
| Sep 30, 2018 | 59.49% |